Naltrexone and nalmefene: Any meaningful difference?

Biological Psychiatry

Volumn 73, Issue 8, 2013, Pages 700-701

  Swift, Robert M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALMEFENE; NALTREXONE; PLACEBO;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FATIGUE; HUMAN; LIVER TOXICITY; NAUSEA; NOTE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VOMITING;

ALCOHOLISM; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; RECURRENCE;

EID: 84875725865     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.03.002     Document Type: Note

References (10)

1. K. Mann, A. Bladström, L. Torup, A. Gual, and W. van den Brink Extending the treatment options in alcohol dependence: A randomized controlled study of as-needed nalmefene Biol Psychiatry 73 2013 706 713
2. J.C. Garbutt Efficacy and tolerability of naltrexone in the management of alcohol dependence Curr Pharm Des 16 2010 2091 2097
3. B.M. Walker, G.R. Valdez, J.P. McLaughlin, and G. Bakalkin Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence Alcohol 46 2012 359 370
4. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al., for the COMBINE Study Research Group, (2006): Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA 295:2003-2017
5. B.J. Mason, E.C. Ritvo, R.O. Morgan, F.R. Salvato, G. Goldberg, B. Welch, and E. Mantero-Atienza A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence Alcohol Clin Exp Res 18 1994 1162 1167
6. R.F. Anton, H. Pettinati, A. Zweben, H.R. Kranzler, B. Johnson, and M.J. Bohn A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence J Clin Psychopharmacol 24 2004 421 428
7. S. Rösner, S. Leucht, P. Lehert, and M. Soyka Acamprosate supports abstinence, naltrexone prevents excessive drinking: Evidence from a meta-analysis J Psychopharmacol 22 2008 11 23
8. A.H. Kline-Simon, D.E. Falk, R.Z. Litten, J.R. Mertens, J. Fertig, M. Ryan, and C.M. Weisner Posttreatment low-risk drinking as a predictor of future drinking and problem outcomes among individuals with alcohol use disorders Alcohol Clin Exp Res 37 suppl 1 2013 E373 E380
9. H.R. Kranzler, H. Tennen, S. Armeli, G. Chan, J. Covault, A. Arias, and C. Oncken Targeted naltrexone for problem drinkers J Clin Psychopharmacol 29 2009 350 357
10. S. Karhuvaara, K. Simojoki, A. Virta, M. Rosberg, E. Löyttyniemi, and T. Nurminen Targeted nalmefene with simple medical management in the treatment of heavy drinkers: A randomized double-blind placebo-controlled multicenter study Alcohol Clin Exp Res 31 2007 1179 1187.